S1PR1 and relapsing-remitting multiple sclerosis: The mechanism of action of fingolimod, which was approved for relapsing-remitting multiple sclerosis (RRMS), activates over sphingosine-1-phosphate receptors (S1PR) expressed on lymphocytes.